Targeting HIF1α Peri-operatively Increased Post-surgery Survival in a Tongue Cancer Animal Model

被引:10
作者
Ahn, Soon-Hyun [1 ]
Choi, Joo Yeon [1 ]
Kim, Dong Wook [1 ]
Lee, Doh Young [1 ]
Jeon, Eun-Hui [1 ]
Jeong, Woo-Jin [1 ]
Paik, Jin Ho [2 ]
机构
[1] Seoul Natl Univ, Coll Med, Dept Otorhinolaryngol Head & Neck Surg, Bundang Hosp, Songnam, South Korea
[2] Seoul Natl Univ, Coll Med, Dept Pathol, Bundang Hosp, Songnam, South Korea
基金
新加坡国家研究基金会;
关键词
SQUAMOUS-CELL CARCINOMA; HISTONE DEACETYLASE INHIBITOR; HYPOXIA-INDUCIBLE FACTORS; STEM-CELLS; HEAD; ECHINOMYCIN; THERAPIES; TRIAL;
D O I
10.1245/s10434-014-4323-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The purpose of the present study was to evaluate the relationship between hypoxia-inducible factor 1 alpha subunit (HIF1 alpha) and tumor initiation in squamous cell carcinoma cell lines and whether targeting HIF1 alpha perioperatively might exert positive effects on survival or recurrence in an animal model. The expression of HIF1 alpha and tumorigenic potential in nude mice was compared using human head and neck squamous cell carcinoma cell lines (SNU1041, SNU1066, SNU1076, PCI01, PCI13, PCI50). A recurrent tongue cancer model was established by first injecting tumor cells in the lateral tongue and then excising the tongue masses for replanting in the neck. The effect of HIF1 alpha inhibitors was assessed using this animal model. We observed good correlation between tumorigenic potential and HIF1 alpha nuclear expression in the cell lines tested. Furthermore, knockdown of HIF1 alpha inhibited tumor growth in the animal model. After in vitro testing of five HIF1 alpha inhibitors, echinomycin and LAQ824 were selected for the animal study. Pre- and postoperative treatment with echinomycin showed significant improvement in postsurgery survival and recurrence. Our results suggested that adjuvant targeting of HIF1 alpha before and after surgery could be a new targeted therapy strategy for squamous cell carcinoma.
引用
收藏
页码:3041 / 3048
页数:8
相关论文
共 26 条
[1]   Detection of Thyroid Cancer Stem Cells in Papillary Thyroid Carcinoma [J].
Ahn, Soon-Hyun ;
Henderson, Ying C. ;
Williams, Michelle D. ;
Lai, Stephen Y. ;
Clayman, Gary L. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2014, 99 (02) :536-544
[2]  
Chang AY, 1998, CANCER-AM CANCER SOC, V82, P292, DOI 10.1002/(SICI)1097-0142(19980115)82:2<301::AID-CNCR8>3.0.CO
[3]  
2-T
[4]   Phase I Pharmacokineitic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor with a Heat Shock Protein-90 Inhibitory Profile, in Patients with Advanced Solid Tumors [J].
de Bono, Johann S. ;
Kristeleit, Rebecca ;
Tolcher, Anthony ;
Fong, Peter ;
Pacey, Simon ;
Karavasilis, Vasilios ;
Mita, Monica ;
Shaw, Heather ;
Workman, Paul ;
Kaye, Stan ;
Rowinsky, Eric K. ;
Aherne, Wynne ;
Atadja, Peter ;
Scott, Jeffrey W. ;
Patnaik, Amita .
CLINICAL CANCER RESEARCH, 2008, 14 (20) :6663-6673
[5]   Promising New Molecular Targeted Therapies in Head and Neck Cancer [J].
Dorsey, Kelly ;
Agulnik, Mark .
DRUGS, 2013, 73 (04) :315-325
[6]   Recent multidisciplinary approach with molecular targeted drugs for advanced head and neck cancer [J].
Fujii, Masato .
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2014, 19 (02) :220-229
[7]   Molecular targeted therapies in head and neck cancer - An update of recent developements - [J].
Goerner, Martin ;
Seiwert, Tanguy Y. ;
Sudhoff, Holger .
HEAD & NECK ONCOLOGY, 2010, 2
[8]   A PHASE-II CLINICAL-TRIAL OF ECHINOMYCIN IN METASTATIC SOFT-TISSUE SARCOMA - AN ILLINOIS-CANCER-CENTER STUDY [J].
GRADISHAR, WJ ;
VOGELZANG, NJ ;
KILTON, LJ ;
LEIBACH, SJ ;
RADEMAKER, AW ;
FRENCH, S ;
BENSON, AB .
INVESTIGATIONAL NEW DRUGS, 1995, 13 (02) :171-174
[9]   Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].
Gregoire, V. ;
Lefebvre, J. -L. ;
Licitra, L. ;
Felip, E. .
ANNALS OF ONCOLOGY, 2010, 21 :v184-v186
[10]  
HEO DS, 1989, CANCER RES, V49, P5167